India is no longer a backup plan for global oncology research.
Clinical trials in India have reached a turning point. With the world’s second-largest population, a rapidly rising cancer burden, and a regulatory environment that has undergone its most significant reforms in two decades, India is now being evaluated and chosen by top-tier global pharmaceutical companies and CROs as a primary destination for cancer clinical trials.
This is not hype. The numbers, the infrastructure, and the pipeline activity all point in the same direction.
Here is a detailed look at why India is becoming the next big hub for oncology clinical trials and what it means for Sponsors, CROs, and Clinical Research professionals planning their next study.
The Cancer Burden in India: A Patient Pool Unlike Any Other
Every oncology trial begins with the same challenge finding enough eligible patients, fast. India solves that problem at scale.
According to the ICMR-National Cancer Registry Programme, India recorded 1.46 million new cancer cases in 2022, projected to reach 1.57 million by 2025. One in nine Indians is estimated to develop cancer in their lifetime. (Source: ICMR-NCRP Cancer Statistics 2023_ncdirindia.org)
What makes this even more valuable is the treatment-naive status of a large proportion of Indian cancer patients. Many have not received prior exposure to advanced targeted therapies or immunotherapy agents that are already standard-of-care in the US or Europe. A scientifically critical advantage for Phase I and Phase II studies, where clean baseline populations directly improve data quality.
Breast, lung, oral, cervical, and colorectal cancers dominate India’s disease profile closely matching the current global oncology pipeline. For sponsors in any of these areas, patient access in India is not a constraint. It is a competitive advantage.
A Regulatory Environment That Has Finally Caught Up
The New Drugs and Clinical Trials (NDCT) Rules, 2019 marked a fundamental shift in how India manages clinical research. The key reforms that directly benefit oncology sponsors:
- Elimination of the mandatory two-year lag for drugs already approved by the FDA or EMA.
- Defined CDSCO review timelines, gradually improving planning certainty.
- Standardised Ethics Committee processes across participating sites.
- Full alignment with ICH E6(R 3) GCP standards.
- Mandatory registration on the Clinical Trials Registry India (CTRI) for transparency.
(Source: CDSCO, Ministry of Health & Family Welfare_cdsco.gov.in)
Indian trial data can now support FDA and EMA submissions, removing the single biggest concern global sponsors previously had about including India in their programs.
The Cost Advantage: Real Numbers, Real Impact
Operational costs in India run 50 to 60% lower than equivalent trials in the United States or Western Europe, covering investigator fees, site management, coordinator time, patient compensation, and local laboratory services. For a multi-site oncology study, that is not a marginal saving. It is a fundamental shift in what a sponsor can accomplish within a fixed R&D budget.
The market reflects this confidence directly. India’s oncology clinical trials market was valued at USD 250.2 million in 2023 and is projected to reach USD 435.7 million by 2030, growing at a CAGR of 8.2%. (Source: Grand View Research, grandviewresearch.com)
Global pharma is not just evaluating India. It is actively investing, and the numbers are accelerating.
Genetic Diversity: India’s Underrated Scientific Advantage
Modern cancer drugs are increasingly designed to work on patients with specific genetic profiles. Testing these drugs only on Western populations gives an incomplete picture of how they will perform across the rest of the world.
India is home to more than 4,600 distinct ethnic communities, each with a unique genetic background shaped over thousands of years. This diversity is scientifically valuable, as trials that include Indian patients generate data that is far more representative of global populations, strengthens regulatory submissions, and supports broader label claims worldwide.
For sponsors developing precision cancer treatments, including India in your trial is not just a cost decision. It is a scientifically smarter one.
Phase I Trials, Immunotherapy and the Expanding Pipeline
Phase I oncology trials, including First-in-Human and dose-escalation studies, are currently the fastest-growing segment of India’s clinical trial market. (Source: Grand View Research, grandviewresearch.com)
Purpose-built early-phase units at leading cancer centres in India now have the infrastructure, trained personnel, and safety monitoring capabilities that Phase I work demands. For global biotech companies seeking faster enrollment and lower costs on early-phase studies, India offers a genuine alternative to US and European locations.
Beyond Phase I, immunotherapy trials, checkpoint inhibitors, CAR-T studies and combination protocols alongside targeted therapy studies for NSCLC, breast cancer, and gastrointestinal cancers are growing rapidly at Indian sites. The global oncology trials market is projected to grow from USD 14.95 billion in 2025 to USD 25.61 billion by 2035, with India positioned to capture an expanding share. (Source: Precedence Research_precedenceresearch.com)
Decentralized Clinical Trials: India Is Moving With the Global Shift
The global decentralized clinical trials market was valued at USD 8.8 billion in 2025 and is projected to reach USD 18.8 billion by 2030, growing at a CAGR of 13.7%. (Source: MarketsandMarkets_ marketsandmarkets.com)
Hybrid trial models combining site visits with telemedicine, home sample collection and local lab tie-ups are being adopted at leading Indian oncology centers. The case for DCTs in India is particularly strong in few elements given that many cancer patients travel three to six hours to reach a tertiary care centre. Reducing that burden directly improves retention and expands recruitment to Tier-2 and Tier-3 cities. CDSCO has signalled openness to hybrid designs, and sponsors are beginning to include Indian sites in broader decentralised frameworks.
What India Still Needs to Get Right
India’s strengths are real, but certain nuances require careful planning and the right local expertise to navigate:
- Site selection requires rigour: Identifying sites that consistently align with international GCP expectations is a critical first step that should never be rushed
- Biomarker infrastructure is evolving: Centralised testing strategies may be needed depending on site location
- Retention planning must be built in from day one: Proactive patient support and hybrid visit models significantly improve long-term study retention
- Regulatory timelines reward early preparation Ethics Committee reviews work most smoothly when groundwork is laid well in advance
None of these are barriers. They are known variables and with the right site management partner on the ground, each one is entirely manageable.
The Role of a CSMO in Unlocking India’s Full Potential
The difference between a successful oncology trial in India and a delayed one often comes down to who is managing operations at the site level.
Clinical Site Management Organizations (CSMOs) operate differently from traditional CROs. While a CRO manages trials at the project level, a CSMO embeds directly within individual sites, providing hands-on support that keeps each location performing to sponsor standards throughout the study.
For oncology trials in India, a specialised CSMO delivers:
- Patient recruitment: Pre-qualified registries and oncologist networks to accelerate enrollment and reduce screening failure rates
- Site training and readiness: GCP alignment, protocol training, and audit preparedness at every location
- Regulatory support: CDSCO submissions, Ethics Committee approvals, and amendment management with genuine local knowledge
- Dedicated monitoring: On-site and remote source data verification, query resolution, and real-time performance reporting
For global sponsors who understand India’s potential but have faced operational inconsistency in the past, a strong CSMO partnership is what converts India’s promise into consistent, high-quality trial execution.
India’s rise as an oncology trial destination is structural driven by regulatory reform, scientific capability, and deliberate global pharma investment. Oncology trials currently represent approximately 41% of all clinical trials conducted globally. (Global Oncology Trends) As that pipeline grows, India’s share will grow with it.
The sponsors building their India capabilities today will carry a real competitive advantage through the rest of this decade.
Planning an oncology trial in India?
Our team supports Global pharmaceutical companies, Sponsors and CROs with site selection, patient recruitment, regulatory navigation, and end-to-end site management. Get in touch to discuss your study at contact@hrapl.in
